Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 105.06 kDa 
• Atom Count: 6005 
• Modelled Residue Count: 702 
• Deposited Residue Count: 930 
• Unique protein chains: 1

4ACD

GSK3b in complex with inhibitor

• DOI: 10.2210/pdb4ACD/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Trichoplusia ni
• Mutation(s): No 


• Deposited: 2011-12-15 Released: 2012-05-16 
• Deposition Author(s): Xue, Y., Ormo, M.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.60 Å
• R-Value Free: 0.226 
• R-Value Work: 0.178 
• R-Value Observed: 0.180 

Literature

Discovery of novel potent and highly selective glycogen synthase kinase-3 beta (GSK3 beta ) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines.

Berg, S., Bergh, M., Hellberg, S., Hogdin, K., Lo-Alfredsson, Y., Soderman, P., von Berg, S., Weigelt, T., Ormo, M., Xue, Y., Tucker, J., Neelissen, J., Jerning, E., Nilsson, Y., Bhat, R.

(2012) J Med Chem 55: 9107-9119

• PubMed: 22489897 
• DOI: 10.1021/jm201724m
• Primary Citation of Related Structures:  
  4ACG, 4ACH, 4ACM, 4ACC, 4ACD


• PubMed Abstract: 
  

Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism. Active forms of GSK3β localize to pretangle pathology including dystrophic neuritis and neurofibrillary tangles in Alzheimer's disease (AD) brain. By using a high throughput screening (HTS) approach to search for new chemical series and cocrystallization of key analogues to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and blood-brain barrier penetrance. The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.

---

Organizational Affiliation: 

Department of Medicinal Chemistry, AstraZeneca R&D, Innovative Medicines CNS & Pain Södertälje, SE-151 85 Södertälje, Sweden. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
GLYCOGEN SYNTHASE KINASE-3 BETA	A, B	465	Homo sapiens	Mutation(s): 0  Gene Names: GSK3B EC: 2.7.11.1 (PDB Primary Data), 2.7.11.26 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for P49841 (Homo sapiens) Explore P49841  Go to UniProtKB:  P49841
PHAROS:  P49841 GTEx:  ENSG00000082701

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
GR9 (Subject of Investigation/LOI)	C [auth A], D [auth B]	3-AMINO-6-{4-[(4-METHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE C21 H23 N7 O3 S FHCSBLWRGCOVPT-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
GR9	IC50:  76   nM  BindingDB
GR9	Ki :  4.900000095367432   nM  PDBBind
GR9	Ki:  4.900000095367432   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.60 Å
• R-Value Free: 0.226 
• R-Value Work: 0.178 
• R-Value Observed: 0.180 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 83.319	α = 90
b = 84.989	β = 90
c = 177.669	γ = 90

Software Package:

Software Name	Purpose
BUSTER	refinement
MOSFLM	data reduction
SCALA	data scaling

Structure Validation

Ligand Structure Quality Assessment  

Entry History 

Deposition Data

• Deposited Date: 2011-12-15 
• Released Date: 2012-05-16 
Deposition Author(s): Xue, Y., Ormo, M.

Revision History  

• Version 1.0: 2012-05-16
  Type: Initial release
  
• Version 1.1: 2012-11-21
  Changes: Database references
• Version 1.2: 2018-01-17
  Changes: Data collection, Database references
• Version 1.3: 2018-02-14
  Changes: Database references